Condition
Advanced/ Metastatic Solid Tumors
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Active Not Recruiting1
Unknown1
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07431073Phase 2Not Yet RecruitingPrimary
Immunotherapy Master Trial for Advanced Cancers
NCT05174637Phase 1Active Not RecruitingPrimary
A Study of FDA018-ADC in Patients With Advanced Solid Tumors
NCT05425602Phase 1UnknownPrimary
A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors
Showing all 3 trials